© The Author 2006. Published by Oxford University Press.
ARTICLE |
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Affiliations of authors: Department of Biomedical Engineering (MRD, WL, CRM, FY, AC), Department of Radiation Oncology (MWD), Duke University, Durham, NC
Correspondence to: Ashutosh Chilkoti, PhD, Box 90281, Durham, NC 27708 (e-mail: chilkoti{at}duke.edu).
Background: Delivery of anticancer therapeutic agents to solid tumors is problematic. Macromolecular drug carriers are an attractive alternative drug delivery method because they appear to target tumors and have limited toxicity in normal tissues. We investigated how molecular weight influences the accumulation of a model macromolecular drug carrier, dextran covalently linked to a fluorophore, in tumors. Methods: We used dextrans with molecular weights from 3.3 kDa to 2 MDa. Vascular permeability, accumulation, and three-dimensional penetration of these dextrans were simultaneously measured in solid tumors via a dorsal skin fold window chamber, intravital laser-scanning confocal microscopy, and custom image analysis. Results: Increasing the molecular weight of dextran statistically significantly reduced its vascular permeability by approximately two orders of magnitude (i.e., from 154 x 10–7 cm/s, 95% confidence interval [CI] = 134 to 174 x 10–7 cm/s, for 3.3-kDa dextran to 1.7 x 10–7 cm/s, 95% CI = 0.7 to 2.6 x 10–7 cm/s for 2-MDa dextran; P<.001, two-sided Kruskal–Wallis test) but increased its plasma half-life, which provided ample time for extravasation (i.e., to enter tumor tissue from the vasculature). Tumor accumulation was maximal for dextrans with molecular weights between 40 and 70 kDa. Dextrans of 3.3 and 10 kDa penetrated deeply (greater than 35 µm) and homogeneously into tumor tissue from the vessel wall. After a 30-minute period, a high concentration was observed only approximately 15 µm from the vessel wall for 40- to 70-kDa dextrans and only 5 µm for 2-MDa dextrans. Conclusions: Increasing the molecular weight of dextran statistically significantly reduced its tumor vascular permeability. Dextrans of 40 and 70 kDa had the highest accumulation in solid tumors but were largely concentrated near the vascular surface.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Matsumoto, H. Yasui, S. Batra, Y. Kinoshita, M. Bernardo, J. P. Munasinghe, H. Utsumi, R. Choudhuri, N. Devasahayam, S. Subramanian, et al. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI PNAS, October 20, 2009; 106(42): 17898 - 17903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Schmidt and K. D. Wittrup A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol. Cancer Ther., October 1, 2009; 8(10): 2861 - 2871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Schluep, J. Hwang, I. J. Hildebrandt, J. Czernin, C. H. J. Choi, C. A. Alabi, B. C. Mack, and M. E. Davis Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements PNAS, July 7, 2009; 106(27): 11394 - 11399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Le, C.-W. Hwang, A. R. Tzafriri, M. A. Lovich, A. Hayward, and E. R. Edelman Vascular Regeneration by Local Growth Factor Release Is Self-Limited by Microvascular Clearance Circulation, June 9, 2009; 119(22): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Smith, J. Blois, H. Yuan, E. Aikawa, C. Ellson, J.-L. Figueiredo, R. Weissleder, R. Kohler, M. B. Yaffe, L. C. Cantley, et al. The antiproliferative cytostatic effects of a self-activating viridin prodrug Mol. Cancer Ther., June 1, 2009; 8(6): 1666 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Egeblad, A. J. Ewald, H. A. Askautrud, M. L. Truitt, B. E. Welm, E. Bainbridge, G. Peeters, M. F. Krummel, and Z. Werb Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy Dis. Model. Mech., September 1, 2008; 1(2-3): 155 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Dreher and A. Chilkoti Toward a Systems Engineering Approach to Cancer Drug Delivery J Natl Cancer Inst, July 4, 2007; 99(13): 983 - 985. [Full Text] [PDF]
|
|
|
|
|
|
N. Tang, G. Du, N. Wang, C. Liu, H. Hang, and W. Liang Improving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin J Natl Cancer Inst, July 4, 2007; 99(13): 1004 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Dreher, W. Liu, C. R. Michelich, M. W. Dewhirst, and A. Chilkoti Thermal Cycling Enhances the Accumulation of a Temperature-Sensitive Biopolymer in Solid Tumors Cancer Res., May 1, 2007; 67(9): 4418 - 4424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Battah, S. Balaratnam, A. Casas, S. O'Neill, C. Edwards, A. Batlle, P. Dobbin, and A. J. MacRobert Macromolecular delivery of 5-aminolaevulinic acid for photodynamic therapy using dendrimer conjugates Mol. Cancer Ther., March 1, 2007; 6(3): 876 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Kano, Y. Bae, C. Iwata, Y. Morishita, M. Yashiro, M. Oka, T. Fujii, A. Komuro, K. Kiyono, M. Kaminishi, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling PNAS, February 27, 2007; 104(9): 3460 - 3465. [Abstract] [Full Text] [PDF]
|
|